Yemen

Reimbursed Care Access

Yemen maintains broad, statutory controls on narcotics and psychotropic substances that prohibit import, manufacture, possession and supply except where expressly authorized for medical or licensed use; most classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine, ayahuasca) are not available for routine medical care and have no public reimbursement pathway. Ketamine, as an established injectable anaesthetic on the WHO Model List of Essential Medicines, is used within medical settings when authorized; however, there is no publicly documented national reimbursement program or published regulatory approval record in Yemeni public registries for newer psychedelic medicines (e.g., esketamine/Spravato) or for therapeutic uses of classical psychedelics outside clinical research. [https://www.unodc.org/cld/en/legislation/yem/law_on_control_and_illicit_trafficking_and_abuse_of_narcotics_and_psychotropic_susbtances/chapters_2_6/articles_2_27/law_control_narcotics.html|UNODC Yemen — Law on Control of Narcotics] [https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists|WHO Model List of Essential Medicines (ketamine listed)].